Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Mifepristone | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | Mifepristone | hsa00030 | Pentose phosphate pathway | 5.07E-03 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Mifepristone | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Mifepristone | hsa00220 | Arginine biosynthesis | 1.54E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Mifepristone | hsa00500 | Starch and sucrose metabolism | 3.86E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Mifepristone | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Mifepristone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Mifepristone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Mifepristone | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.29E-02 | 2 | P40925, P15104 | MDH1, GLUL | More | | Mifepristone | hsa00790 | Folate biosynthesis | 4.05E-02 | 2 | Q92820, P42330 | GGH, AKR1C3 | More | | Mifepristone | hsa00910 | Nitrogen metabolism | 2.93E-02 | 2 | P22748, P49448 | CA4, GLUD2 | More | | Mifepristone | hsa00970 | Aminoacyl-tRNA biosynthesis | 5.32E-03 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | | Mifepristone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Mifepristone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Mifepristone | hsa00983 | Drug metabolism - other enzymes | 6.37E-06 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Mifepristone | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | | Mifepristone | hsa03008 | Ribosome biogenesis in eukaryotes | 1.46E-02 | 4 | Q9NYH9, P78345, Q9BVP2, Q9GZY0 | UTP6, RPP38, GNL3, NXF2; NXF2B | More | | Mifepristone | hsa03013 | RNA transport | 4.11E-03 | 12 | P52298, Q09161, O14893, P61326, Q9GZY0, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5, Q53GS7 | NCBP2, NCBP1, GEMIN2, MAGOH, NXF2; NXF2B, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3, GLE1 | More | | Mifepristone | hsa03015 | mRNA surveillance pathway | 9.78E-03 | 6 | O43148, Q16537, P61326, Q9GZY0, P52298, Q53GS7 | RNMT, PPP2R5E, MAGOH, NXF2; NXF2B, NCBP2, GLE1 | More | | Mifepristone | hsa04060 | Cytokine-cytokine receptor interaction | 1.74E-04 | 17 | P14784, P27930, P14778, P08476, P26842, Q06643, Q13651, Q9HBE5, P25024, Q9UBD3, P47992, P01375, P09341, P19875, P18510, P01730, Q93038 | IL2RB, IL1R2, IL1R1, INHBA, CD27, LTB, IL10RA, IL21R, CXCR1, XCL2, XCL1, TNF, CXCL1, CXCL2, IL1RN, CD4, TNFRSF25 | More | | Mifepristone | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.36E-04 | 9 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, Q13651, P14784, P01375 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB, TNF | More | | Mifepristone | hsa04062 | Chemokine signaling pathway | 5.37E-03 | 9 | P25024, P09341, P19875, P07948, P42338, P19174, P63218, P50151, P43250 | CXCR1, CXCL1, CXCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6 | More | | Mifepristone | hsa04064 | NF-kappa B signaling pathway | 1.86E-10 | 22 | P10415, Q13489, P25963, P51617, O00463, Q13546, P14778, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q13315, P24522, O75293, P09341, P19875, Q06643, Q9UNE0 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, RIPK1, IL1R1, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, ATM, GADD45A, GADD45B, CXCL1, CXCL2, LTB, EDAR | More | | Mifepristone | hsa04071 | Sphingolipid signaling pathway | 6.18E-05 | 9 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2 | More | | Mifepristone | hsa04080 | Neuroactive ligand-receptor interaction | 1.83E-04 | 8 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1 | More | | Mifepristone | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Mifepristone | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Mifepristone | hsa04145 | Phagosome | 4.31E-06 | 11 | P63261, Q15080, P14598, Q13509, P68371, Q13488, P05164, P78380, O60603, P35443, P13765 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | | Mifepristone | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Mifepristone | hsa04210 | Apoptosis | 1.09E-03 | 12 | Q13315, P10415, Q13489, O76075, P25963, P01375, P24522, Q16548, Q13077, P43234, P18848, Q14643 | ATM, BCL2, BIRC3, DFFB, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, CTSO, ATF4, ITPR1 | More | | Mifepristone | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Mifepristone | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Mifepristone | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Mifepristone | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Mifepristone | hsa04340 | Hedgehog signaling pathway | 4.63E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | Mifepristone | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Mifepristone | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Mifepristone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Mifepristone | hsa04540 | Gap junction | 3.53E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Mifepristone | hsa04612 | Antigen processing and presentation | 1.41E-07 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Mifepristone | hsa04613 | Neutrophil extracellular trap formation | 9.71E-07 | 18 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, P21730, P21462, P63261 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1, ACTG1 | More | | Mifepristone | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Mifepristone | hsa04621 | NOD-like receptor signaling pathway | 7.18E-04 | 13 | Q14643, P01568, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q13546, Q05823, P01375, P49913, P12838 | ITPR1, IFNA21, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RIPK1, RNASEL, TNF, CAMP, DEFA4 | More | | Mifepristone | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Mifepristone | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Mifepristone | hsa04640 | Hematopoietic cell lineage | 2.66E-04 | 13 | P13612, P14778, P27930, P11215, P15144, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | Mifepristone | hsa04650 | Natural killer cell mediated cytotoxicity | 2.53E-09 | 14 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O75015, P26717, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Mifepristone | hsa04657 | IL-17 signaling pathway | 8.05E-04 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Mifepristone | hsa04658 | Th1 and Th2 cell differentiation | 8.53E-12 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Mifepristone | hsa04659 | Th17 cell differentiation | 1.46E-09 | 17 | P25963, Q04759, Q16539, P19174, P01730, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, CD3E, CD3G, CD247 | More | | Mifepristone | hsa04660 | T cell receptor signaling pathway | 8.34E-08 | 18 | P01375, P25963, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Mifepristone | hsa04662 | B cell receptor signaling pathway | 1.07E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Mifepristone | hsa04664 | Fc epsilon RI signaling pathway | 1.29E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Mifepristone | hsa04666 | Fc gamma R-mediated phagocytosis | 9.96E-03 | 5 | P23528, P49006, P06396, P14598, P17252 | CFL1, MARCKSL1, GSN, NCF1, PRKCA | More | | Mifepristone | hsa04668 | TNF signaling pathway | 2.36E-03 | 9 | P01375, O00463, Q13489, Q16539, P25963, P09341, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, CXCL1, BCL3, TRAF1, MMP9 | More | | Mifepristone | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Mifepristone | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Mifepristone | hsa04720 | Long-term potentiation | 1.15E-03 | 6 | P16298, P51812, P18848, P22694, Q02750, Q14643 | PPP3CB, RPS6KA3, ATF4, PRKACB, MAP2K1, ITPR1 | More | | Mifepristone | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Mifepristone | hsa04724 | Glutamatergic synapse | 2.81E-02 | 4 | P43003, P63218, P50151, P15104 | SLC1A3, GNG5, GNG10, GLUL | More | | Mifepristone | hsa04725 | Cholinergic synapse | 3.86E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | | Mifepristone | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.06E-03 | 8 | P14778, P22694, Q16539, P19174, P42338, Q14643, P24723, Q04759 | IL1R1, PRKACB, MAPK14, PLCG1, PIK3CB, ITPR1, PRKCH, PRKCQ | More | | Mifepristone | hsa04912 | GnRH signaling pathway | 2.62E-02 | 3 | P18848, Q14643, P22694 | ATF4, ITPR1, PRKACB | More | | Mifepristone | hsa04913 | Ovarian steroidogenesis | 4.05E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Mifepristone | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Mifepristone | hsa04915 | Estrogen signaling pathway | 1.67E-03 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | | Mifepristone | hsa04918 | Thyroid hormone synthesis | 7.24E-04 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | Mifepristone | hsa04920 | Adipocytokine signaling pathway | 5.84E-03 | 6 | P25963, P33121, Q9Y478, Q04759, Q96RR4, P01375 | NFKBIA, ACSL1, PRKAB1, PRKCQ, CAMKK2, TNF | More | | Mifepristone | hsa04922 | Glucagon signaling pathway | 2.11E-02 | 4 | P22694, P06737, P18848, Q14643 | PRKACB, PYGL, ATF4, ITPR1 | More | | Mifepristone | hsa04925 | Aldosterone synthesis and secretion | 4.95E-02 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Mifepristone | hsa04927 | Cortisol synthesis and secretion | 3.17E-05 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Mifepristone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 9.12E-04 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | Mifepristone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Mifepristone | hsa04934 | Cushing syndrome | 4.06E-02 | 5 | Q14643, P22694, P49841, Q9UJU2, O00170 | ITPR1, PRKACB, GSK3B, LEF1, AIP | More | | Mifepristone | hsa04964 | Proximal tubule bicarbonate reclamation | 2.93E-02 | 2 | P22748, P49448 | CA4, GLUD2 | More | | Mifepristone | hsa04970 | Salivary secretion | 4.49E-02 | 4 | P22694, Q14643, P17252, P49913 | PRKACB, ITPR1, PRKCA, CAMP | More | | Mifepristone | hsa04972 | Pancreatic secretion | 1.99E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Mifepristone | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Mifepristone | hsa04975 | Fat digestion and absorption | 9.50E-04 | 1 | O14494 | PLPP1 | More | | Mifepristone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Mifepristone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P07948 | CXCL1, CXCL2, PLCG1, CXCR1, LYN | More | | Mifepristone | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Mifepristone | hsa05132 | Salmonella infection | 1.81E-05 | 15 | P51617, P25963, P01375, Q9UJU2, P63261, Q13546, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, O60282, Q13509, P68371 | IRAK1, NFKBIA, TNF, LEF1, ACTG1, RIPK1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, KIF5C, TUBB3, TUBB2C | More | | Mifepristone | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Mifepristone | hsa05135 | Yersinia infection | 4.26E-02 | 6 | P13612, P06239, Q16539, P01375, P49841, P01732 | ITGA4, LCK, MAPK14, TNF, GSK3B, CD8A | More | | Mifepristone | hsa05140 | Leishmaniasis | 3.13E-05 | 9 | P14598, P13765, O60603, P25963, P01375, P29350, P49006, P51617, Q15080 | NCF1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MARCKSL1, IRAK1, NCF4 | More | | Mifepristone | hsa05144 | Malaria | 1.80E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | | Mifepristone | hsa05145 | Toxoplasmosis | 4.06E-03 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Mifepristone | hsa05146 | Amoebiasis | 1.05E-08 | 13 | Q13751, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | LAMB3, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Mifepristone | hsa05152 | Tuberculosis | 3.11E-03 | 9 | Q13488, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Mifepristone | hsa05161 | Hepatitis B | 1.61E-03 | 10 | P17252, P14780, P25963, Q13485, P01375, P10415, P84022, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, SMAD4, TNF, BCL2, SMAD3, IRAK1, TLR2, STAT4 | More | | Mifepristone | hsa05163 | Human cytomegalovirus infection | 2.64E-02 | 7 | P42338, P63218, P50151, P01106, P14778, Q13651, P30101 | PIK3CB, GNG5, GNG10, MYC, IL1R1, IL10RA, PDIA3 | More | | Mifepristone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.22E-04 | 12 | P42338, P62879, P63218, P50151, P09341, P19875, P19174, P16298, Q02750, P07948, P01106, P0CG47 | PIK3CB, GNB2, GNG5, GNG10, CXCL1, CXCL2, PLCG1, PPP3CB, MAP2K1, LYN, MYC, UBB | More | | Mifepristone | hsa05169 | Epstein-Barr virus infection | 1.27E-02 | 9 | P01106, Q13547, P42338, P07948, P30101, Q13761, O75293, P07766, P20963 | MYC, HDAC1, PIK3CB, LYN, PDIA3, RUNX3, GADD45B, CD3E, CD247 | More | | Mifepristone | hsa05170 | Human immunodeficiency virus 1 infection | 3.39E-06 | 26 | P42338, Q02750, P62879, P63218, P50151, P16298, P01375, Q05397, P17252, O00463, P30101, Q14643, P01730, P51617, P25963, O60603, Q13315, O95067, P19174, P07766, P20963, P10415, Q13619, Q93034, Q9Y6Q5, P20333 | PIK3CB, MAP2K1, GNB2, GNG5, GNG10, PPP3CB, TNF, PTK2, PRKCA, TRAF5, PDIA3, ITPR1, CD4, IRAK1, NFKBIA, TLR2, ATM, CCNB2, PLCG1, CD3E, CD247, BCL2, CUL4A, CUL5, AP1M2, TNFRSF1B | More | | Mifepristone | hsa05202 | Transcriptional misregulation in cancer | 1.02E-09 | 19 | Q12778, Q15532, Q13315, P41732, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P04637, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, TP53, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Mifepristone | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Mifepristone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Mifepristone | hsa05205 | Proteoglycans in cancer | 2.66E-02 | 8 | Q14643, P63261, P04637, P14780, P17252, O60603, Q13635, P08962 | ITPR1, ACTG1, TP53, MMP9, PRKCA, TLR2, PTCH1, CD63 | More | | Mifepristone | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Mifepristone | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | | Mifepristone | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Mifepristone | hsa05216 | Thyroid cancer | 3.59E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Mifepristone | hsa05217 | Basal cell carcinoma | 1.20E-03 | 5 | Q13635, P49841, Q9UJU2, P04637, P24522 | PTCH1, GSK3B, LEF1, TP53, GADD45A | More | | Mifepristone | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | | Mifepristone | hsa05222 | Small cell lung cancer | 2.38E-03 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Mifepristone | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | | Mifepristone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 6.30E-05 | 10 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, CD4 | More | | Mifepristone | hsa05310 | Asthma | 6.09E-07 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Mifepristone | hsa05321 | Inflammatory bowel disease | 6.54E-11 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Mifepristone | hsa05322 | Systemic lupus erythematosus | 3.30E-05 | 14 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, Q16778, O60814, P68431, P12814, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1, SSB | More | | Mifepristone | hsa05323 | Rheumatoid arthritis | 2.32E-03 | 5 | P01375, P13765, P10747, P09341, O60603 | TNF, HLA-DOB, CD28, CXCL1, TLR2 | More | | Mifepristone | hsa05332 | Graft-versus-host disease | 8.48E-08 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Mifepristone | hsa05418 | Fluid shear stress and atherosclerosis | 4.26E-02 | 6 | P14598, P14780, P63261, P04637, P10415, Q92974 | NCF1, MMP9, ACTG1, TP53, BCL2, ARHGEF2 | More | | |